Literature DB >> 19850104

Deletion of both the C3a and C5a receptors fails to protect against experimental autoimmune encephalomyelitis.

Theresa N Ramos1, Jillian E Wohler, Scott R Barnum.   

Abstract

Multiple sclerosis (MS) is an autoimmune disease in which inflammation, leukocyte infiltration, and ultimately, demyelination occur as a result of innate and adaptive immune-mediated mechanisms. The pathophysiological role of the complement system, a major component of innate immunity, in the development and progression of experimental autoimmune encephalomyelitis (EAE), the animal model for MS has been extensively examined. Previous studies from our lab have shown that the complement receptor for the anaphylatoxin C3a, but not for C5a plays an important role in EAE. Based on the important contributions of the complement anaphylatoxin receptors to other inflammatory conditions in the CNS, we reasoned that deletion of both receptors may reveal underlying interactions between them that are important to EAE pathology. We performed EAE in C3aR/C5aR double knockout mice (C3aR/C5aR(-/-)) and observed delayed onset of disease but no attenuation of disease severity compared to wild type mice. Interestingly there was trend toward greater infiltration of CD4(+), but not CD8(+) T cells, in C3aR/C5aR(-/-) mice with EAE, suggesting altered trafficking of these cells. Antigen-specific T cells isolated from C3aR/C5aR(-/-) mice during acute EAE produced elevated levels of TNF-alpha, but markedly reduced levels of IFN-gamma and IL-12 compared to wild type mice. It remains unclear how the changes in these disease parameters contribute to the loss of the protective effect seen in C3aR(-/-) mice, however our data indicate a level of cross-modulation between the C3aR and C5aR during EAE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19850104      PMCID: PMC2784262          DOI: 10.1016/j.neulet.2009.10.045

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

1.  Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock.

Authors:  J Kildsgaard; T J Hollmann; K W Matthews; K Bian; F Murad; R A Wetsel
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

Review 2.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

3.  Differential expression of beta 2-integrins and cytokine production between gammadelta and alphabeta T cells in experimental autoimmune encephalomyelitis.

Authors:  Sherry S Smith; Scott R Barnum
Journal:  J Leukoc Biol       Date:  2007-10-10       Impact factor: 4.962

4.  The C5a chemoattractant receptor mediates mucosal defence to infection.

Authors:  U E Höpken; B Lu; N P Gerard; C Gerard
Journal:  Nature       Date:  1996-09-05       Impact factor: 49.962

5.  C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a.

Authors:  Nien-Jung Chen; Christine Mirtsos; Daniel Suh; Yong-Chen Lu; Wen-Jye Lin; Colin McKerlie; Taeweon Lee; Helene Baribault; Hui Tian; Wen-Chen Yeh
Journal:  Nature       Date:  2007-02-25       Impact factor: 49.962

Review 6.  Complement and demyelinating disease: no MAC needed?

Authors:  Scott R Barnum; Alexander J Szalai
Journal:  Brain Res Rev       Date:  2006-01-26

7.  Disruption of the C5a receptor gene fails to protect against experimental allergic encephalomyelitis.

Authors:  Rachael Reiman; Craig Gerard; Iain L Campbell; Scott R Barnum
Journal:  Eur J Immunol       Date:  2002-04       Impact factor: 5.532

8.  Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis.

Authors:  Laura Boos; Iain L Campbell; Robert Ames; Rick A Wetsel; Scott R Barnum
Journal:  J Immunol       Date:  2004-10-01       Impact factor: 5.422

9.  Deletion of both ICAM-1 and C3 enhances severity of experimental autoimmune encephalomyelitis compared to C3-deficient mice.

Authors:  Sherry S Smith; Michael Ludwig; Jillian E Wohler; Daniel C Bullard; Alex J Szalai; Scott R Barnum
Journal:  Neurosci Lett       Date:  2008-07-06       Impact factor: 3.046

10.  Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats.

Authors:  B P Morgan; M Griffiths; H Khanom; S M Taylor; J W Neal
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

View more
  6 in total

1.  Evidence for anti-inflammatory effects of C5a on the innate IL-17A/IL-23 axis.

Authors:  Markus Bosmann; J Vidya Sarma; Gelareh Atefi; Firas S Zetoune; Peter A Ward
Journal:  FASEB J       Date:  2011-12-27       Impact factor: 5.191

2.  The C5 convertase is not required for activation of the terminal complement pathway in murine experimental cerebral malaria.

Authors:  Theresa N Ramos; Meghan M Darley; Sebastian Weckbach; Philip F Stahel; Stephen Tomlinson; Scott R Barnum
Journal:  J Biol Chem       Date:  2012-06-11       Impact factor: 5.157

Review 3.  Role and mechanism of action of complement in regulating T cell immunity.

Authors:  Jason R Dunkelberger; Wen-Chao Song
Journal:  Mol Immunol       Date:  2010-06-18       Impact factor: 4.407

4.  Mast Cells are Important Modifiers of Autoimmune Disease: With so Much Evidence, Why is There Still Controversy?

Authors:  Melissa A Brown; Julianne K Hatfield
Journal:  Front Immunol       Date:  2012-06-07       Impact factor: 7.561

5.  Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.

Authors:  Andrea Facciabene; Francesco De Sanctis; Stefano Pierini; Edimara S Reis; Klara Balint; John Facciponte; Jens Rueter; Masahiro Kagabu; Paola Magotti; Evripidis Lanitis; Robert A DeAngelis; Ronald J Buckanovich; Wenchao C Song; John D Lambris; George Coukos
Journal:  Oncoimmunology       Date:  2017-06-08       Impact factor: 8.110

Review 6.  The role of the complement system in Multiple Sclerosis: A review.

Authors:  Nil Saez-Calveras; Olaf Stuve
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.